Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: Assessment with the Neuropathic Pain Scale

Current Medical Research and Opinion

Volumn 20, Issue SUPPL. 2, 2004, Pages

  Argoff, Charles E ^a   Galer, Bradley S ^b,c   Jensen, Mark P ^d,e   Oleka, Napoleon ^b   Gammaitoni, Arnold R ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Analgesics; Diabetic neuropathy; Low back pain; Ostherpetic neuralgia; Pain scale

Indexed keywords

ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; GABAPENTIN; LIDOCAINE;

ADULT; AGED; ARTICLE; BURNING SENSATION; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LIVER DYSFUNCTION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHIC PAIN SCALE; PAIN ASSESSMENT; PAPULE; PARESTHESIA; POSTHERPETIC NEURALGIA; RATING SCALE; SKIN DISEASE; TOPICAL ANESTHESIA;

ADMINISTRATION, CUTANEOUS; AGED; ANESTHETICS, LOCAL; CHRONIC DISEASE; DIABETIC NEUROPATHIES; FEMALE; HERPES ZOSTER; HUMANS; LIDOCAINE; LOW BACK PAIN; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 13144282687     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X12960     Document Type: Article

References (38)

1. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4
2. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56
3. Guo HR, Tanaka S, Cameron LL, et al. Back pain among workers in the United States: national estimates and workers at high risk. Am J Ind Med 1995;28:591-602
4. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29:79-86
5. Rizzo JA, Abbott TA, III, Berger ML. The labor productivity effects of chronic backache in the United States. Med Care 1998;36:1471-88
6. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-8
7. Lin C-C. Comparison of the effects of perceived self-efficacy on coping with chronic cancer pain and coping with chronic low back pain. Clin J Pain 1998;14:303-10
8. Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998:16:1768-70
9. Fields HL, Rowbotham MC. Multiple mechanisms of neuropathic pain: a clinical perspective. In: Gebhart GF, Hammond DL, et al., editors. Proceedings of the 7th World Congress on Pain. Seattle: 1ASP Press; 1994. p. 437-54
10. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34
11. Chung K, Lee BH, Yoon YW, Chung JM. Sympathetic sprouting in the dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain model. J Comp Neurol 1996;376:241-52
12. McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993;363:543-6
13. Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res Manag 2002;7:81-92
14. Moskowitz MH. Pharmacotherapy of neuropathic low back pain. Curr Pain Headache Rep 2003;7:178-87
15. Deyo RA. Drug therapy for back pain: which drugs help which patients? Spine 1996;21:2840-50
16. Ehrlich GE. Low back pain. Bull World Health Organ 2003;81:671-6
17. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-15
18. Masubuchi Y, Saito H, Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J Pharmacol Exp Ther 1998;287:208-13
19. Weinblatt ME. Drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl 1989;83:7-10
20. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. J Am Med Assoc 1998;280:1837-42
21. Argoff CE. Topical analgesics: a review of recent clinical trials and their application to clinical practice. Adv Stud Nursing 2003;3(7A):S642-7
22. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000;59:245-9
23. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111-7
24. Gammaitoni AR, Davis MW Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40
25. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332-8
26. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989;38:333-8
27. Laird JM, Carter AJ, Grauert M, Cervero F. Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 2001;134:1742-8
28. Zhang JM, Li H, Munir MA. Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine. Pain 2004;109:143-9
29. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004;12:253-5
30. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003;4:321-30
31. Argoff CE. Lidocaine patch 5% and the management of chronic pain. South Med J 2002;95:781
32. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 2000;16:205-8
33. Hines R, Keaney D, Moskowitz MH, Prakken S. Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med 2002;3:361-5
34. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain 2002;18:297-301
35. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
36. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
37. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8
38. Galer BS, Gammaitoni AR, Burch F. Impact of treatment with the lidocaine patch 5% on pain, stiffness, and physical function in patients with osteoarthritis (Abstr). Poster presented at 64th Annual Assembly of the American Academy of Physical Medicine & Rehabilitation, October 9-12, 2003, Chicago, IL. (Poster #96). 2003